Distribution of capsule and O types in Klebsiella pneumoniae causing neonatal sepsis in Africa and South Asia: A meta-analysis of genome-predicted serotype prevalence to inform potential vaccine coverage.
Stanton TD., Keegan SP., Abdulahi JA., Amulele AV., Bates M., Heinz E., Hooda Y., Hu W., Jain K., Kanwar S., Magobo R., Olwagen CP., Tembo JM., Sonda T., Strysko J., Tigoi CC., Amin SA., Bittinger K., Cornick J., Foster-Nyarko E., Gumbi W., Hotwani A., Iqbal N., Jones SM., Kabir F., Khan W., Musyani CL., McGann CM., Mittal V., Moustafa AM., Musicha P., Mwansa JCL., Ndumba ML., Odih EE., Omuoyo DO., Pearse O., Phillips LT., Planet PJ., Rasool AA., Rodrigues CMC., Sands K., Tanmoy AM., Theiller E., Zuza AM., Basu S., Chan GJ., Iregbu KC., Mazarati J-B., Alemayehu SS., Walsh TR., Zahra R., Dramowski A., Fwoloshi S., Labi A-K., Madrid L., Obeng-Nkrumah N., Ojok D., Wadugu BD., Whitelaw AC., Bethou A., Bhargava A., Jindal A., Nanavati RN., Prasad PS., Sastry A., Farooqi JQ., Ghanchi N., Jehan F., Khan E., Agarwal RK., Aiken AM., Berkley JA., Coffin SE., Feasey NA., Govender NP., Hamer DH., Madhi SA., Nisar MI., Saha SK., Saha S., Sankar MJ., Wyres KL., Holt KE.
BackgroundKlebsiella pneumoniae causes ~20% of sepsis in neonates, with ~40% crude mortality. A vaccine administered to pregnant women, protecting against ≥70% of K. pneumoniae infections, could avert ~400,000 cases and ~80,000 deaths annually, mostly in Africa and South Asia. Vaccine formulations targeting the capsular polysaccharide (K) or lipopolysaccharide (O) antigens are in development. Global K. pneumoniae populations display extensive K and O diversity, necessitating a polyvalent vaccine-targeted to the serotypes associated with neonatal disease in relevant geographical regions. We investigated the prevalence of K and O types associated with neonatal sepsis in Africa and South Asia to inform maternal vaccine design.Methods and findingsWe analysed 1,930 K. pneumoniae neonate blood isolates from 13 surveillance studies across 35 sites in 13 countries. We used pathogen whole-genome sequencing to predict K and O serotypes and adjust for local transmission clusters, and Bayesian hierarchical meta-analysis to estimate K and O prevalence overall and per region, treating site as a random effect. Eighty-seven K loci were identified. KL2, KL102, KL25, KL15, and KL62 accounted for 49% of isolates. We estimate that 20 K loci, combining the eight most prevalent per region, could cover 72.9% of all infections (95% credible interval: [69.4%, 76.5%]) and ≥70% in each of Eastern, Western, and Southern Africa and South Asia. Preliminary findings from three sites suggested sufficient temporal stability of K loci to maintain 20-valent K vaccine coverage over 5-10 years, but more longitudinal data are needed to support this prediction. O types were far less diverse (n = 14 types). We estimate the top-5 (O1⍺β,2⍺, O1⍺β,2β, O2⍺, O2β, and O4) would cover 86.2% [82.6, 89.9%] of total infections (76%-92% per region), while the top-10 would cover ~99% of infections in all four regions. The main limitations of our study are the reliance on genome sequences to predict K and O serotypes (as serological typing is not available) and a lack of longitudinal data to explore stability of antigen prevalence over time.ConclusionsNeonatal sepsis is associated with diverse K and O types, with substantial geographic and temporal variation even after adjusting for localised transmission clusters. Despite this, a single 20-valent K vaccine could theoretically cover ≥70% of infections in all target regions. Locally-targeted vaccines could achieve higher coverage with lower valency, but are less feasible. In principle, very high coverage could be achieved with lower valency O-based vaccines, however, the protective efficacy against disease of antibodies targeting the O antigen remains uncertain. Further research is needed on cross-reactivity, antigen exposure, and stability of antigens over time, to better inform vaccine development.